A multi-center, randomized, double-blind, cross-over, placebo-controlled clinical trial to evaluate efficacy and safety of oxcarbazepine p.o. (300-1200 mg/day) as adjuvant therapy for impulsivity and aggressive behavior in conduct disorders in adolescents
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2007
At a glance
- Drugs Oxcarbazepine (Primary)
- Indications Conduct disorder
- Focus Therapeutic Use
- Sponsors Novartis
- 29 Nov 2007 Status changed from in progress to completed.
- 01 Nov 2006 New trial record.